We sought to determine whether AML blasts with variable degrees of NY-ESO-1 mRNA expression were producing sufficient protein expression (below the level of detection by immunoblotting) to allow for recognition by HLA compatible NY-ESO-1 specific CD8+ T-cells. This evidence concerns the gene CD8A and acute myeloid leukemia.